Gear Up for Novartis (NVS) Q3 Earnings: Wall Street Estimates for Key Metrics

Analysts on Wall Street project that Novartis (NVS) will announce quarterly earnings of $2.26 per share in its forthcoming report, representing an increase of 9.7% year over year. Revenues are projected to reach $13.9 billion, increasing 8.4% from the same quarter last year.The consensus EPS estimate for the quarter has remained unchanged over the last 30 days. This reflects how the analysts covering the stock have collectively reevaluated their initial estimates during this timeframe.Before a company announces its earnings, it is essential to take into account any changes made to earnings estimates. This is a valuable factor in predicting the potential reactions of investors toward the stock. Empirical research has consistently shown a strong correlation between trends in earnings estimate revisions and the short-term price performance of a stock.While investors typically use consensus earnings and revenue estimates as indicators of quarterly business performance, exploring analysts' projections for specific key metrics can offer valuable insights.In light of this perspective, let's dive into the average estimates of certain Novartis metrics that are commonly tracked and forecasted by Wall Street analysts.Analysts expect 'Revenues- Oncology- Tafinlar + Mekinist- Total' to come in at $555.75 million. The estimate points to a change of +4.1% from the year-ago quarter.The combined assessment of analysts suggests that 'Revenues- Net sales to third parties' will likely reach $14.07 billion. The estimate suggests a change of +9.8% year over year.Analysts' assessment points toward 'Revenues- Oncology- Kisqali- Total' reaching $1.29 billion. The estimate suggests a change of +64.2% year over year.Analysts predict that the 'Revenues- Immunology- Cosentyx- Total' will reach $1.72 billion. The estimate indicates a change of +1.9% from the prior-year quarter.The average prediction of analysts places 'Revenues- Oncology- Tasigna- US' at $119.43 million. The estimate indicates a year-over-year change of -47.2%.The consensus estimate for 'Revenues- Oncology- Promacta/Revolade- US' stands at $180.08 million. The estimate points to a change of -41.2% from the year-ago quarter.According to the collective judgment of analysts, 'Revenues- Immunology- Cosentyx- US' should come in at $990.42 million. The estimate suggests a change of -0.3% year over year.It is projected by analysts that the 'Revenues- Cardiovascular- Entresto- US' will reach $927.94 million. The estimate points to a change of +1.8% from the year-ago quarter.The collective assessment of analysts points to an estimated 'Revenues- Oncology- Tasigna- ROW' of $149.03 million. The estimate indicates a year-over-year change of -22.8%.The consensus among analysts is that 'Revenues- Oncology- Tafinlar + Mekinist- ROW' will reach $320.55 million. The estimate indicates a year-over-year change of +4.4%.Analysts forecast 'Revenues- Oncology- Promacta/Revolade- ROW' to reach $267.72 million. The estimate indicates a year-over-year change of +1.8%.Based on the collective assessment of analysts, 'Revenues- Immunology- Cosentyx- ROW' should arrive at $734.58 million. The estimate indicates a change of +4.9% from the prior-year quarter. View all Key Company Metrics for Novartis here>>> Novartis shares have witnessed a change of +6.9% in the past month, in contrast to the Zacks S&P 500 composite's +0.2% move. With a Zacks Rank #3 (Hold), NVS is expected closely follow the overall market performance in the near term. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .Radical New Technology Could Hand Investors Huge GainsQuantum Computing is the next technological revolution, and it could be even more advanced than AI.While some believed the technology was years away, it is already present and moving fast. Large hyperscalers, such as Microsoft, Google, Amazon, Oracle, and even Meta and Tesla, are scrambling to integrate quantum computing into their infrastructure.Senior Stock Strategist Kevin Cook reveals 7 carefully selected stocks poised to dominate the quantum computing landscape in his report, Beyond AI: The Quantum Leap in Computing Power.Kevin was among the early experts who recognized NVIDIA's enormous potential back in 2016. Now, he has keyed in on what could be "the next big thing" in quantum computing supremacy. Today, you have a rare chance to position your portfolio at the forefront of this opportunity.See Top Quantum Stocks Now >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Novartis AG (NVS): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks Weiter zum vollständigen Artikel bei Zacks